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Objective: The efficiency of HSV-tk/GCV system is not high because of insufficient gene transfer and incompletely
initiative of host antineoplastic potency. The present study was designed to assess the antitumor efficacy of
tk-MCP-1 on ovarian cancer in vitro and vivo.
Methods: A novel bicistronic expression system can help to improve the expression level of a gene in a stable
manner. pLXSN/tk-MCP-1 co-expressing tk and MCP-1 genes was constructed using a pLXSN retroviral vector and
an internal ribosome entry site sequence by restriction enzyme. Western blot was performed to determine tk and
MCP-1 expression in the infected SKOV3. The GCV-sensitively tumoricidal activities of SKOV3/tk-MCP-1 with or
without monocytes were compared to those of SKOV3 expressing HSV-tk or MCP-1. We investigated the growth of
subcutaneous tumors in SCID mice immuno-reconstituted, and evaluated the antitumor effect of MCP-1 in
conjunction with suicide gene.
Results: The significant GCV-sensitively tumoricidal activity of pLXSN/tk-MCP-1 was observed when compared with
those of pLXSN/tk, pLXSN/MCP-1 and pLXSN/neo, especially when monocytes were added. The growth of
subcutaneous tumors in SCID mice immuno-reconstituted was markedly suppressed by co-delivery of HSV-tk and
MCP-1 genes, and the enhanced antitumor effect was associated with the recruitment of monocytes.
Conclusion: These results demonstrated pLXSN/tk-MCP-1 presented an enhanced antitumor effects on ovarian
cancer by orchestration of immune responses.
Keywords: Herpes simplex virus thymidine kinase, Monocyte chemoattractant protein-1, Gene therapy, Ovarian
neoplasma, SCIDBackground
Ovarian cancer is the leading cause of death from gyne-
cologic cancers. Every year, approximately 200,000
women are diagnosed with ovarian cancer and more
than 100,000 women died of ovarian cancer around the
world [1,2]. Due to inherent and acquired chemoresis-
tance of ovarian cancer, the effect of current therapies
for advanced or metastatic ovarian cancer is far from
satisfying [3]. This underscores the imperative to adopt
new strategies to fight against ovarian cancer effectively.* Correspondence: fnrong@163.com; kongbeihua@sdu.edu.cn
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reproduction in any medium, provided the orSuicide gene therapy is one of these strategies with anti-
tumor effect [4,5]. However, its efficacy for the treatment
of cancer is limited because of the insufficient gene trans-
fection and insufficient induction of host immunity [6-8] .
The bystander killing effect is a mechanism counting on
host immunological function, which could kill the neigh-
boring uninfected tumor cells produced by suicide gene
HSV-tk/GCV system and finally strongly enhance the cap-
acity against the tumor cells [9,10]. Recently, increasing
studies have been carried out to optimize the suicide gene
therapy in combination with immune genes.
MCP-1 is one of thte chemokine responsible for the
recruitment and activation of mononuclear cells, and it can
induce nonspecific and specific antitumor immunity
[11,12]. Therefore, we hypothesized that tk-MCP-1 fusion
gene could significantly enhance the efficacy of suicide genetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elicited anti-tumor immunity in ovarian cancer.
Materials and methods
Recombinant retroviruses
We designed the PCR or RT-PCR primers for HSV-tk,
MCP-1 and IRES. HSV-tk: 50-GCGCGTATGGCTTCG
TACCC-30 and 50-TCCTTGCGTGTTTCAGTTAGTC-30.
MCP-1: 50-CGGAATTCATATGCAGCCAGATGCAATC-30
and 50-CGGGATCCTTA TCAAGTCTTCGGAGT-30. IRES:
50- CGATCGATCTCCACGTGGCGGC-30 and 50- CCTGA
TAATCCAATTCGCTTTAT-30. Total RNA was extracted
from human peripheral blood mononuclear cells (PBMC)
followed by RT-PCR to generate MCP-1 gene fragment
with 5 min at 95°C, 1 min at 94°C, 1 min at 58°C and
1 min at 72°C, up to 35 cycles. By Restriction Enzyme
cutting site, EcoRI - XhoI internal ribozyme entry site
(IRES) fragment of poliomyelitis virus, we got linear
pLXSN. Then it was inserted into the herpes simplex virus
thymidine kinase gene fragment from pWZLneotkglyCD
with BamHI-EcoRI to generate the tk-IRES-neo, and
pLXSN/tk was obtained by insertion of tk-IRES-neo into
Linear pLXSN. pLXSN fragment combined with MCP-1
gene fragment to generate pLXSN/MCP-1. MCP-1
gene fragment was inserted into pLXSN/tk-IRES-neo
to form pLXSN/tk-MCP-1. The above plasmids were
verified by PCR. Retroviruses containing pLXSN/tk-
MCP-1, pLXSN/tk, pLXSN/MCP-1 and pLXSN/neo
respectively were generated by transfecting PA317 cells
using liposome, and transfected cells were selected by
G418 at diverse concentrations. The titer of retrovirus
was determined (Figure 1-A).
RT-PCR
Total RNA was extracted as described previously and
RT-PCR was performed comprising 33 thermal cycles of
95°C for 5 min, 94°C for 1 min, 58°C for 1 min, 72°C for
1 min and 72°C for 7 min. The same condition was used
in MCP-1 amplification except 30 cycles in total.
Cell culture and retrovirus infection
The human epithelial ovarian cancer cell line SKOV3 was
used in vitro and vivo. SKOV3 cells were infected with
supernatant of retrovirus at high titre containing pLXSN/
tk-MCP-1(5.3 × 105 CFU/ml), pLXSN/tk(6.0× 105 CFU/
ml), pLXSN/MCP-1(4.8 × 105 CFU/ml) and pLXSN/neo
(4.5× 105 CFU/ml) at various volumes (100 μl, 200 μl,
500 μl or 1 ml), supplied with RPMI-1640 with 10% NBS
to 2 ml, and then added polybrene (the concentration of
polybrene at 8 μg/ml). Three hours later, cells were
supplied with RPMI-1640 with 10% NBS to 8 ml and
cultured for 2–3 days at 37°C in a 5% CO2 atmosphere.
G418 at 600 μg/ml was added into 4 kinds of cells. Ten
days later, cells which survived in medium containingG418 at 600 μg/ml named SKOV3/tk-MCP-1, SKOV3/tk,
SKOV3/MCP-1 and SKOV3/neo.
Western blot
Proteins were extracted using protein extraction reagent,
48 h after transfection and save at −20°C, following a
protocol provided by the manufacture. MCP-1 protein
and tk protein expressions were detected with western
blot. Proteins with equal amount were separated by
appropriate concentration SDS-polyacrylamide gel electro-
phoresis and transferred onto PVDF membrane (Millipore,
Billeriaca, MA, USA). The membranes were blocked in
TBST for 1 h at room temperature and then incubated with
primary antibodies fo tk (1:500, Abcam, United Kingdom),
MCP-1 (1:500, Santa Cruz Biotechnology) and β-actin
(1:5000, Boston, MA) overnight at 4°C The membranes
were then washed three times with TBST, followed by
incubating with HRP-labeled secondary antibodies (KPL,
Gaithersburg, MD, USA) (1:5000). Bound antibody was
visualized using ECL detection reagent (Merck, Darmstadt,
Germany).
Antitumor effect of GCV
The number of viable cells were determined by 3-(4,
5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide
(MTT) assay. There were 4 experimental groups including
SKOV3/tk, SKOV3/MCP-1, SKOV3/tk-MCP-1 and SKOV3/
neo. Cells were re-suspended in fresh culture medium at
the density of 2× 104 cells/ml, 180 μl suspension were incu-
bated in 96-well plates. The cells were treated with 20μl
GCV at the concentrations of 10−2, 10−1, 1, 10, 102,
103 μg/ml for 72 h at 37°C in 5% CO2 incubator. SKOV3/
tk-MCP-1 and SKOV3/neo seeded by same way was added
GCV (1.0 μg/ml, 0.1 μg/ml) incubated for 24, 48, 72 and
96 h to detect time toxicity of GCV. 20μl Sodium Chloride
was added to controls. The activity of the mitochondria,
reflecting cellular growth and viability, was evaluated by
measuring the optical density at 490 nm on microtiter
plate reader.
We also detected the antitumor effect of human
monocytes on gene modified ovarian cells by MTT:
There were 3 experimental groups including SKOV3/
MCP-1, SKOV3/tk-MCP-1 and SKOV3/neo. Mononuclear
cells were used as effectors, and tumor cells above-
mentioned were used as target. Cells were seeded in the
96-well plates at the density of 5 × 103 cells/well. Then
mononuclear were added at different ratio of effector to
target (20:1, 10:1, 5:1), incubated at 37°C in 5% CO2 incu-
bator for 4 days, cytotoxicity were determined.
The surviving rate of mixed tumor cell under the action
of GCV only was determined by MTT. Briefly, there were
3 experimental groups (including SKOV3/tk, SKOV3/tk-
MCP-1 and SKOV3/neo). The above cells infected by
different gene at different proportion (100%, 90%, 70%,
Figure 1 The plasmid characterization and confirmation of expression of tk and MCP-1 by RT-PCR and western blot. A. The construction
of the bicistronic recombinant replication-defective retroviruses vector pLXSN/tk-MCP-1, pLXSN/tk and pLXSN/MCP-1. B. Restriction enzyme
analysis of pLXSN/tk-MCP-1 showed that tk and/or MCP-1 gene fragment had insert in the proper orientation in the vector of pLXSN, pLXSN/tk,
pLXSN/MCP-1 and pLXSN/neo. a: EcoR I + BamH I, b: Nco I + BamH I, c: Sal I + BamH I, d: EcoR I, M: Marker. C. The expression of tk and MCP-1
protein were detected by western blot 48 h after transfection. a: SKOV3/tk. b: SKOV3/MCP-1. c: SKOV3/neo. d: SKOV3/tk-MCP-1.
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were added in 10 μg/ml GCV The surviving rate of cells
were determined by MTT incubated in 96-well plates for
4 days at 37°C in 5% CO2 incubator.
Next we detect the surviving rate of mixed tumor cell
under the action of GCV plus human monocytes by
MTT. Each kind of cells and wild SKOV3 were seeded
in 96-well plates as the same way. Then 5 × 104 human
monocytes were added at the ratios of 10:1(effectors: target).
All cells were incubated for 4 days at 37°C in 5% CO2
incubator after supplied 10 μg/ml GCV. Cells without
GCV were used as control group.
Detection of cell apoptosis rate, cell cycle and the expres-
sion of CD25 (IL-2R) and CD44v6 by flow cytometer:
SKOV3/tk, SKOV3/tk-MCP-1 and SKOV3/neo were seeded
in 25 cm flask. After cells adherenced, we added human
monocytes at the ratios of 10:1(effectors: target) and 0.5 μg/
ml GCV, and then incubated cells for 48 h at 37°C in 5%
CO2 incubator.Animal experiments
The present study was approved by the local animal
Care Committee and is in compliance with Chinese laws
for animal protection. 6 to 8 weeks old, weight-matched
female combined immune deficiency mice (C.B17/SCID)
were purchased from Weitonglihua experimental animal
limited company. Animals were housed in the animal
facility of the Medical College of Shandong university of
China. Enzyme-linked immunosorbent assay (ELISA) for
the IgG of C.B17/SCIDs in serum was performed to elim-
inate immune leakage according to the manufacturer’s
protocol. Human mononuclear cells were isolated from
human peripheral blood mononuclear cells by Ficoll-
Hypaque discontiguous density gradient centrifugation
technique and were re-suspended in fresh RPMI 1640
medium without NBS at a density of 8× 107cells/ml. 0.5 ml
cell suspension was injected into abdominal cavity of per C.
B17/SCID for immunologic reconstitution. Twenty-four
hours after celiac immunologic reconstitution, SKOV3/
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cell lines were inoculated by intraperitoneal injection at a
density of 2 × 107 cell/SCID. According to the cells inocu-
lated, all experimental C.B17/SCIDs were divided into 4
groups, i.e. SKOV3/neo, SKOV3/tk, SKOV3/MCP-1 and
SKOV3/tk-MCP-1 group (10 SCIDs/group). SKOV3/neo
group was used as control group and the rest groups were
experimental groups. We injected GCV 75 mg/kgd intra-
peritoneally for 5 days after tumor transplantation, then,
observed the biologic characteristics of SCID, such as
spirit, appetite and abdominal bulge.
The survival periods of 4 SCID mice selected randomly
from each groups were recorded from being successfully
transplanted human ovarian carcinoma cells to natural
death. The rest 6 SCID mice of each groups were sacrificed
as soon as the appearance of death in the control group.
The number of macrophages infiltrated the tumor
sites was examined by flow cytometry. Briefly, monoplast
suspension of tumor tissue was prepared by trituration.
Cells were re-suspended in PBS at the density of 1 × 106
cells/ml followed by addition of 10 μl human CD14/PE
(Pharmingen USA) antibody mixing thoroughly. After
30 min of activation away from light at 20°C-25°C, flow
cytometry was used to detect the amount of macrophages.
The TNF-α protein level was analysised by western blot.
The cell apoptosis rate, cell cycle and the expression of
CD25 (IL-2R) and CD44v6 in tumor cells were detected
by flow cytometer.
Statistical analysis
The SPSS version 13.0 software was used for statistical
analysis. Results were reported as means ± standard devi-
ation (SD). The statistical differences between group was
assessed by q test. Kaplan-Meier survival curves were
generated with the use of SPSS 13.0. Comparisons of
median survivals were performed using log-rank tests.
Alpha (α) level was set at 0.05.
Results
Confirmation of plasmid
Restriction enzyme analysis of plasmid DNA showed
that tk and MCP-1 gene fragment were inserted in the
proper orientation in the vector of pLXSN named
pLXSN/tk-MCP-1, so had pLXSN/tk, pLXSN/MCP-1
and pLXSN/neo (Figure 1-B).
Packaging and transfection of pLXSN/tk, pLXSN/MCP-1,
pLXSN/tk-MCP-1 and pLXSN recombinantretroviral vector
The recombinant retroviral vectors including pLXSN/tk,
pLXSN/MCP-1, pLXSN/tk-MCP-1 and pLXSN/neo, were
transfected into retroviral packaging cell line PA317 by
DOTAP, respectively. Stable retroviral vector-produced
lines were generated by expanding the G418-resistant
(> 500 μg/ml) colonies, named PA317/tk (pLXSN/tktransferred), PA317/MCP-1 (pLXSN/MCP-1 transferred),
PA317/tk-MCP-1(pLXSN/tk- MCP-1 transferred) and
PA317/neo (pLXSN transferred) respectively. The super-
natant containing the packaged retroviruses was harvested,
filtered and titrated 4.5× 105 CFU/ml-6.0 ×105 CFU/ml
determined in NIH3T3 cells. SKOV3 cells were infected
with the high titre recombinant retrovirus (pLXSN/tk,
pLXSN/MCP-1, pLXSN/tk-MCP-1 and pLXSN/neo), while
SKOV3 tansfected pLXSN/neo was used as the control
group. Stable retroviral vector-produced cell lines were
generated by expanding the G418-resistant (600 μg/ml)
colonies, named SKOV3/neo, SKOV3/tk, SKOV3/MCP-1
and SKOV3/tk-MCP-1 respectively.Validation of tk and MCP-1 expression
Western blot analysis demonstrated that MCP-1 protein
was expressed in the SKOV3/MCP-1 and SKOV3/
tk-MCP-1, and tk protein was expressioned in the
SKOV3/tk and SKOV3/tk-MCP-1 (Figure 1-C).Antitumor effect
As shown in Figure 2-A, the viability of cells dose-
dependently reduced. GCV at the density of 10-2-103 μg/
ml had obvious antitumor effect on SKOV3/tk
(IC50:2.24± 0.23 μg/ml) and SKOV3/tk-MCP-1 (IC50:
2.06± 0.31 μg/ml). The IC50 value of SKOV3/tk and
SKOV3/tk-MCP-1 significantly dropped when compared
to that of SKOV3/neo (P< 0.05). There was no significant
difference between SKOV3/MCP-1 group and control
groups (P> 0.05). Besides, the beginning cytotoxic time of
0.1 μg/ml GCV and 1.0 μg/ml GCV was both 48 h, and
the 96 h kill rate of 0.1 μg/ml GCV and 1.0 μg/ml GCV
against SKOV3/tk-MCP-1 was 40± 2.19% and 90± 4.55%
respectively (P< 0.05) (Figure 2-B).
The antitumor effect of monocytes on ovarian cancer
cells: The maximum lethality rate of SKOV3/MCP-1 and
SKOV3/tk-MCP-1 was 29± 1.25% and 23± 2.18% respec-
tively, comparing to 1.8 ± 0.64% of SKOV3/neo (P< 0.05).
We found that the lethal effect of monocytes on tumor
cells was effector-dependent, and the maximum lethality
rate appeared at the ratio of 20:1(Figure 2-C).
The survival rate of SKOV3/tk and SKOV3/tk-MCP-1
incubating with SKOV3 in different ratio was evaluated
after addition GCV or GCV plus monocytes (Figure 2-D).
When 10 μg/ml GCV was added, only 10% of SKOV3/tk
or SKOV3/tk-MCP-1 could kill about 40% of tumor cells.
When the ratio of SKOV3/tk or SKOV3/tk-MCP-1 to
SKOV3 was 50%, there were about 80% of tumor cells
killed. But cytotoxin did not appear with SKOV3/neo
(P < 0.05). Only 10% of tk-MCP-1 +GCV+monocytes
system could kill about 70% of tumor cells, while 40%
of tk-MCP-1 +GCV +monocytes system could kill
about 90% of tumor cells.
Figure 2 Antitumor effection. A: MTT assay of GCV on ovarian cancer cells. B: GCV at the density of 0.1 μg/ml, the beginning cytotoxic was
48 h and 40% kill rate at 96 h, however, the beginning cytotoxic was 48 h and 90% kill rate at 96 h when GCV at the density of 1.0 μg/ml. C:
Lethal effect of mononuclear macrophage on SKOV3/MCP-1 and SKOV3/tk-MCP-1 was determined by MTT assay. D: There is a synergistic
antitumor effect when cooperated tk-MCP-1 +GCV system with mononuclear macrophage.
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rate of SKOV3/tk-MCP-1 (13.48± 1.01%) was obviously
higher than those of SKOV3/tk (9.50 ± 1.33%) and SKOV3/
neo (2.19± 0.56%) (P<0.05), S phase of SKOV3/tk
(38.31± 1.67%) was lower than that of SKOV3/tk-MCP-1
(52.92± 1.78%) (P<0.05)(Table 1).
The percentage of positive cell represents content of
CD25 (IL-2r) or CD44v6 (Figure 3), CD25 of SKOV3/tk
(20.00 ± 2.04%) and SKOV3/tk-MCP-1 (38.82 ± 2.48%)
was obviously higher than that of SKOV3/neo
(8.73 ± 1.65%)(P < 0.05). CD25 of SKOV3/tk-MCP-1 was
significantly higher than that of SKOV3/tk (P<0.05).
CD44v6 of SKOV3/tk (6.66±2.01%) and SKOV3/tk-MCP-1
(6.51±1.03%) was significant lower than that of control
group (40.74±3.58%) (P<0.01).Table 1 Post-treatment apoptotic rate and cell cycle
analysis (x s)
SKOV3/neo SKOV3/tk SKOV3/tk-MCP-1
Apoptotic rate (%) 2.19 ± 0.56 9.50 ± 1.33 13.48 ± 1.01
G0/G1 (%) 53.90 ± 1.66 53.10 ± 1.21 40.28 ± 1.11
S (%) 19.34 ± 0.65 38.31 ± 1.67 52.92 ± 1.78
G2/M (%) 26.76 ± 1.01 8.59 ± 1.25 6.80 ± 1.11Antitumor effects of recombinant gene in vivo
Forty SCIDs (IgG < 5 μg/ml) were injected PBMC intra-
peritoneally. Three weeks later immune reconstruction
was successfully established in SCID mouse (human
IgG > 5 μg/ml). The ratio of successful tumor transplant-
ation was 100%. The tumor was widespread in peritoneal
cavity. The reduction of abdominal bulge and the im-
provement of spirit and appetite of tk-MCP-1group were
greater than tk or MCP-1, and the condition of control
group had no amelioration. The survival period of tk-
MCP-1 group was significantly longer than tk or MCP-1
group, followed by the control group (35 ± 2.94 d,
25 ± 2.16 d, 26 ± 2.58 d and 15 ± 3.16 d, P < 0.05). There
was no significant difference between tk and MCP-1
groups (P > 0.05) (Figure 4-F). The ovarian tumors of the
tk-MCP-1 group shrank significantly, followed by the tk
or MCP-1 group. However, the tumor of the control
group was still widespread in peritoneal cavity and cavi-
tas pelvis There was no significant difference between tk
and MCP-1 groups (P > 0.05) (Figure 4A–E). As shown
in Figure 5 and Table 2, flow cytometry examination
revealed that the number of macrophages infiltrated the
tumor tissues in the control group, tk or MCP-1 group
and tk-MCP-1 group increased in order (P < 0.05), so did
Figure 3 CD25 of SKOV3/tk (20.00± 2.04%) and SKOV3/tk-MCP-1 (38.82 ± 2.48%) was obviously higher than SKOV3/neo (8.73± 1.65%)
(P<0.05). CD25 of SKOV3/tk-MCP-1 was significantly higher than that of SKOV3/tk (P< 0.05). CD44v6 of SKOV3/tk (6.66 ± 2.01%) and SKOV3/tk-MCP-1
(6.51 ± 1.03%) was significantly lower than that of control group (40.74 ± 3.58%) (P< 0.01).
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There was no significant difference between tk and
MCP-1 groups (P > 0.05).
Discussion
It is clear that expression of a single transgene is unlikely to
be sufficient to eradicate ovarian cancer that is diagnosed
late in disease progression. Many studies have demon-
strated that HSV-tk combined with cytokine therapy
followed by GCV has a higher chance of success [13-18].
MCP-1 (CCL2) has been successfully used to treat hepato-
cellular carcinoma by recombinant adenovirus vector (rAd)
s expressing with HSV-tk [19]. Because several preclinical
studies have demonstrated that genotoxic potential is not
identical among all retroviral vector systems [20], and IRES
could enable two different gene expressed simultaneously
[21], we constructed pLXSN/tk-MCP-1 which co-expresses
tk and MCP-1, and assessed the antitumor effect of
pLXSN/tk-MCP-1 on ovarian cancer.
MCP-1 plays a crucial role in tumor tissue inflammatory
response by activating and inducing the infiltration of
macrophages, and in the regulation of adhesion factors
expression which causes the contact ot macrophages with
tumor cells. Once the effector cells get close to target cells,
macrophages present the effect of antitumor by swallowing
and killing pathogen, corpus alienum, senile and mutant
cells, participating in nonspecific immune reaction and
specific immunity, dealing with antigenic properties and
presenting antigenic information to T or B lymphocyte[22-24]. Yamashiro et al. [25] found that the increasing
amount of activated peripheral blood monouclear cells
transfected MCP-1 gene infiltrating in tumor could restrain
the growth of tumor. The present study suggested that
MCP-1 could activate human mononuclear macrophage
and carries a role in antitumor reaction, but the growth of
tumor cells in control group was scarcely refrained. The
more the effector cells, the stronger the tumoricidal effect
of mononuclear macrophage was. Here our data provided
strong evidence that MCP-1 had the antitumor reaction by
activating mononuclear macrophage.
Bystander effect plays an important role in suicide
gene therapy of tumor. Many studies have demonstrated
that bystander effect might be due to immunization.
Ramesh et al. [26] confirmed that the integrity of host
immune was essential for suicide gene therapy. They
performed RT-PCR after HSV-tk +GCV treatment and
found the release of cytokines (TNF-α, IL-1, IL-6, IFN-α
and GM-CSF mRNA) consistently increased [27].
Immunohistochemical analysis for tumor tissue after
HSV-tk/GCV treatment showed a great quantity of CD4+,
CD8+ lympholeukocyte recruiment. Gagandeep et al. [28]
found that many immunocells infiltrated in tumor after
HSV-tk+GCV therapy and cytokines released to cause
hemorrhagic necrosis of tumor. The externalization of
these cytokines depended on tumor cytotoxic effect and
revoked up-regulation of immunological regulators such
as MHC, B7 and ICAM-1. Accordingly, the mechanism of
bystander effect depends on the transition of tumor
Figure 4 A–E. The ovarian tumors of the tk-MCP-1 group shrank significantly, followed by the tk or MCP-1 group. However, the tumor
of the control group was still widespread in peritoneal cavity and cavitas pelvis. F. Kaplan-Meier survival analysis of mice intraperitoneally
transplanted with diverse tumor cells. a. SKOV3/tk-MCP-1 b. SKOV3/MCP-1 c. SKOV3/tk d. SKOV3/neo.
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activated state which initiates anti-tumor effect of immunal
inflammatory system.
The use of cytokine gene therapy combined with suicide
gene/prodrug can enhance bystander effect by reinforcing
immune function. Chen et al. [29] injected recombined
adenovirus expressed both IL-2 gene and HSV-tk gene to
colon carcinoma model with hepatic metastasis, and
found that the link of tk gene and IL-2 possess was more
sufficient than individual gene therapy.
We demonstrated that the therapy of a combining suicide
gene (HSV-tk and MCP-1) significantly improved the
antitumor efficiency on SKOV3 cells by bicistronic recom-
binant replication-defective retroviruses vector pLXSN/tk-
MCP-1 constructed in our lab. The bicistronic pLXSNco-expressing tk and MCP-1 linked by a bicistronic unit
including poliomyelitis virus IRES was designed by
proteinaceous translation initiation model inside chain of
eukaryotic cell. The single upstream promoter can
transcribe the same mRNA from two genes, and then the
gene in the upstream is translated in eukaryocyte cap-
dependent manner, while the downstream gene can be
translated and expressed under the control of IRES in
cap-independent manner, avoiding the influence on
expression of the two genes at the regulation level of
transcription.
The maximum concentration of MCP-1 and the result of
chemotactic index of MCP-1-mediated migration showed
that SKOV3/tk-MCP-1 could secrete MCP-1 possessed
chemotactic activity. Furthermore, our study showed a
Figure 5 Flow cytometry examination revealed that the number of macrophages (A) infiltrated the tumor tissues in the control group,
tk or MCP-1 group and tk-MCP-1 group increased in order (P <0.05), so did TNF-α protein level from the activated microphages. There
was no significant difference between tk and MCP-1 groups (P> 0.05) (B). a. SKOV3/neo b. SKOV3/tk c. SKOV3/MCP-1 d. SKOV3/tk-MCP-1.
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SKOV3/tk-MCP-1+GCV. MCP-1 is one of the major
chemoattractants for mononuclear macrophage which candirectly eradicate tumor cells, the importance is MCP-1
significantly induced a low survival rate when transduced
cells and untransduced cells are cultured together in
Table 2 Mean Percent of macrophages in each group
Groups Percent of macrophages (%) (x s)
tk-MCP-1 8.70 ± 0.35
MCP-1 5.20 ± 0.28
HSV-tk 4.90 ± 0.24
The control group 0.90 ± 0.25
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effect by immunal inflammatory system showed 10%
tk+can induce a 70% tumor cells death rate. Combined
HSV-tk with MCP-1 gene therapy is a powerful approach
for the treatment of ovarian cancer. They not only could
play their antitumor role respectively, but also could creat
synergistic action which could enhance the anti-tumor
immune reactions. Many immune effector cells aggregate
to tumor site via the expression of MCP-1 activity and
provoke nonspecific immune reaction and specific immun-
ity, not only boosting the cytotoxic effect of GCV but also
enhancing immune reaction to reinforce the bystander
effect.
In order to explore the synergic antineoplastic mech-
anism and the influence on tumorous biological behavior
of combined HSV-tk and MCP-1 gene, we investigated
apoptosis and cell cycle. The results indicated that with
the depressant effect of treatment on ovarian cells, FCM
emerged manifest apoptotic peak, and that the propor-
tion of S stage phase in cell cycle significantly increased
at the same time compared with the control group. We
also detected that the apoptosis rate of SKOV3 caused
by HSV-tk-MCP-1 +GCV (13.48 ± 1.01%) was significant
higher than that of HSV-tk +GCV (9.50 ± 1.33%). Simi-
larly, the proportion of S stage of the former markedly
increased than the latter.
These studies open the possibility that the prodrug
GCV can blockage the cell cycle at S stage. The fact that
the expression of CD25 significant raised after SKOV3
transfected tk-MCP-1 gene detected by FACS suggests
that the immunogenicity of tumor cells may be enhanced
after the treatment of combined tk and MCP-1 gene
therapy. A study showed that the abnormal expression of
adhesion molecule of cell surface CD44 and its var CD44v6
is closely related to infiltration, metastasis and dys-
prognosis of malignancy [30,31]. We also demonstrated
that the expression of CD44v6 was significantly lower after
the administration of GCV on tumor cells successfully
transfected SKOV3/tk and SKOV3/tk-MCP-1 gene, which
suggests that suicide gene therapy may retroconverse the
infiltration, metastasis of malignant cells and the expression
of MCP-1 has no significant effect.
Freeman and colleagues [32] reported that suicide
gene therapy could shift tumorous microenvironment
from immune suppression to immunostimulation in order
to initiate antitumor effect by inflammation, indicating thatbystander effect relies in part on an intact immune system
following tk/GCV gene therapy. We used SCID mouse as
tumor vehicle, which had defect in both cellular and
humoral immune function, to explore the antitumor
mechanism of human immunal system. SCID mouse is an
ideal preclinical empirical animal model because it can
either load human tumor or be immunal functional recon-
structed by human immunocyte. In this study, SKOV3/tk,
SKOV3/MCP-1 or SKOV3/tk-MCP-1 cell line was intra-
peritoneally transplanted after immune reconstruction
being successfully established in SCID mouse 3 weeks
after intraperitoneally transplantation of PBMC. The
tumor was widespread in peritoneal cavity, mainly in
diaphragm, liver and mesentery. We demonstrated that
tk-MCP-1 fusion gene had significantly tumoricidal effect
in vivo partly depending on the effector of TNF-α from
the activated of mononuclear macrophages induced by
MCP-1.
Conclusions
In conclusion, our data suggest that combined suicide
gene therapy with immune gene therapy generates
significantly stronger therapeutic antitumor effects by
different mechanism and distinct link. This research
provided sound evidence for preclinical research of
ovarian carcinoma treatment, and might become the
theoretical of a novel therapeutic strategy.
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